ADHD
Attention-deficit/hyperactivity disorder (ADHD) involves persistent difficulties with attention, impulsivity or restlessness that can affect everyday life.
TerminatedNCT03597503
What is this study about?Researchers are comparing SPN-810 and placebo, tracking side effects to assess safety in young people with ADHD.
This study ended early.
Multiple locations, including Culver CityADHDMedication studyAges 12–17
- Countries
- United States
- Sponsor
- Supernus Pharmaceuticals, Inc. (Pharmaceutical company)
CompletedNCT02618408
What is this study about?Researchers compared SPN-810 (18 mg), SPN-810 (36 mg) and placebo, tracking side effects to assess safety and tolerability in children with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including RogersADHDMedication studyAges 6–12
- Countries
- United States
- Sponsor
- Supernus Pharmaceuticals, Inc. (Pharmaceutical company)
CompletedNCT02618434
What is this study about?Researchers compared SPN-810 (18 mg), SPN-810 (36 mg) and placebo, tracking side effects to assess safety and tolerability in children with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including ChandlerADHDMedication studyAges 6–12
- Countries
- United States
- Sponsor
- Supernus Pharmaceuticals, Inc. (Pharmaceutical company)
TerminatedNCT02691182
What is this study about?Researchers are studying SPN-810, tracking side effects to assess long-term safety in children with ADHD.
This study ended early.
In OrlandoADHDMedication studyAges 6–17
- Countries
- United States
- Sponsor
- Supernus Pharmaceuticals, Inc. (Pharmaceutical company)
CompletedNCT02675400
Official study titleTreatments for Fathers With Attention Deficit/Hyperactivity Disorder (ADHD) and Their At-Risk Children (Fathers Too)
This study has finished and is no longer accepting participants.
In SeattleADHDMedication studyAges 21–55
- Countries
- United States
- Sponsor
- Seattle Children's Hospital
CompletedNCT01388530
Official study titleAn Eight-Week, Open Trial Pilot Investigation of Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
In Los AngelesADHDDevice studyAges 7–14
- Countries
- United States
- Sponsor
- University of California, Los Angeles
CompletedNCT01351064
This study has finished and is no longer accepting participants.
In IndianapolisADHDInterventional studyAges 5–12
- Countries
- United States
- Sponsor
- Indiana University
CompletedNCT02257216
Official study titleA Randomized, Sequential Parallel, Double-Blind, Placebo- Controlled Medical Food Study for the Safety and Efficacy of Vayarin® in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
Multiple locations, including MariettaADHDPlacebo comparisonAges 18–60
- Countries
- United States
- Sponsor
- Enzymotec
CompletedNCT04561713
Official study titleDevelopment of a Virtual Reality Application for the Diagnosis of Childhood ADHD: an Exploratory Study
This study has finished and is no longer accepting participants.
In BordeauxADHDInterventional studyAges 8–12
- Countries
- France
- Sponsor
- University Hospital, Bordeaux
TerminatedNCT01017263
Official study titleVyvanse and Glucose Intolerance in Children With ADHD and Obesity
This study ended early.
In DurhamADHDMedication studyAges 8–17
- Countries
- United States
- Sponsor
- Duke University
RecruitingNCT07478458
Multiple locations, including GenoaADHDDevice studyAges 13–18
- Countries
- Italy
- Sponsor
- Istituto Giannina Gaslini
Not Yet RecruitingNCT07570381
Official study titleBiomarker Discovery for Predicting Autism Spectrum Disorder and Attention/Hyperactivity Disorders, and Identification of Environmental Factors Influencing Anxiety and Depression in Children, Adolescents, and Young Adults
This study isn't recruiting yet.
In ExeterADHD, Depression, ...Observational studyAges 6 months–25 years
- Countries
- United Kingdom
- Sponsor
- University of Exeter